Skip to main content

Drug Interactions between ado-trastuzumab emtansine and Integrilin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

eptifibatide ado-trastuzumab emtansine

Applies to: Integrilin (eptifibatide) and ado-trastuzumab emtansine

MONITOR CLOSELY: Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs. In clinical trials, fatal cases of hemorrhage occurred in patients receiving trastuzumab emtansine in addition to anticoagulant and antiplatelet therapy.

MANAGEMENT: Caution is recommended and additional monitoring should be considered if trastuzumab emtansine must be used with anticoagulant or antiplatelet drugs. In general, monitoring of platelet counts is recommended prior to each dose of trastuzumab emtansine. If platelet counts decrease to less than 50,000/mm3 (Grade 3 or higher), discontinue trastuzumab emtansine until platelet counts increase to 75,000/mm3 or higher (Grade 1 or less).

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2022) "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer